Hybridoma technology is a biotechnological approach used for the commercial production of monoclonal antibodies. Monoclonal antibodies are laboratory-produced antibodies that are specific to a particular antigen. They have a wide range of applications in medicine, diagnostics, and research.

Hybridoma technology involves the fusion of a specific type of immune cell, called a B-cell, with a tumor cell to create a hybrid cell known as a hybridoma. The B-cell provides the ability to produce antibodies, while the tumor cell provides the ability to grow indefinitely. The hybridoma cells are then cultured in the laboratory, where they continuously produce large quantities of a specific monoclonal antibody.

This technology has revolutionized the production of antibodies, as it allows for the production of highly specific antibodies in large quantities. These antibodies can be used for various purposes, including the diagnosis and treatment of diseases, as well as in research and development of new drugs.